An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and isan effective therapeutic vaccine in guinea pigs

Journal of Virology

Volumn 87, Issue 7, 2013, Pages 3930-3942

  Skoberne, Mojca ^a   Cardin, Rhonda ^b   Lee, Alexander ^a   Kazimirova, Ana ^a   Zielinski, Veronica ^a   Garvie, Danielle ^a   Lundberg, Amy ^a   Larson, Shane ^a   Bravo, Fernando J ^b   Bernstein, David I ^b   Flechtner, Jessica B ^a   Long, Deborah ^a  

^a Cambridge Discovery Park   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEN 003; HERPES SIMPLEX VACCINE; MM 2; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GUINEA PIG; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE; SYMPTOMATOLOGY; T LYMPHOCYTE; VIRUS SHEDDING;

ADJUVANTS, IMMUNOLOGIC; ANALYSIS OF VARIANCE; ANIMALS; BACULOVIRIDAE; BLOTTING, WESTERN; CERCOPITHECUS AETHIOPS; CLONING, MOLECULAR; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; GUINEA PIGS; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; IMMUNOTHERAPY; MICE; NEUTRALIZATION TESTS; T-LYMPHOCYTES; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; VIRUS SHEDDING;

ANIMALIA; CAVIA; HERPES; HUMAN HERPESVIRUS 2; MUS;

EID: 84875548674     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02745-12     Document Type: Article

References (69)

1. Looker KJ, Garnett GP, Schmid GP. 2008. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull. World Health Organ. 86:805-812.
2. Johnston C, Saracino M, Kuntz S, Magaret A, Selke S, Huang M-L, Schiffer JT, Koelle DM, Corey L, Wald A. 2012. Standard-dose and high-dose antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet 379:641-647.
3. Cohen GH, Dietzschold B, Leon MP, Long D, Golub E, Varrichio A, Pereira L, Eisenberg RJ. 1984. Localization and synthesis of an antigenic determinant of herpes simplex virus glycoprotein D that stimulates the production of neutralizing antibody. J. Virol. 49:102-108.
4. Muggeridge MI, Robert SR, Isola VJ, Cohen GH, Eisenberg RJ (ed). 1990. Herpes simplex virus glycoproteins. Elsevier, New York, NY.
5. Corey L. 1999. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection:two randomized controlled trials JAMA 282: 331-340.
6. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P, Dubin G, GSK Herpes Vaccine Efficiency Study Group. 2002. Glycoprotein- D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661.
7. Belshe RB, Leone PA, Bernstein DI, Wald A, Levin MJ, Stapleton JT, Gorfinkel I, Ashley Morrow RLA, Ewell MG, Stokes-Riner A, Dubin G, Heineman TC, Schulte JM, Deal CD, Herpevac Trial for Women. 2012. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 366:34-43.
8. Burke RL, Goldbeck C, Ng P, Stanberry L, Ott G, Nest GV. 1994. The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine. J. Infect. Dis. 170:1110-1119.
9. Harrison CJ, Miller RL, Bernstein DI. 2001. Reduction of recurrent HSV disease using imiquimod alone or combined with a glycoprotein. Vaccine 19:1820-1826.
10. Hoshino Y, Dalai SK, Wang K, Pesnicak L, Lau TY, Knipe DM, Cohen JI, Straus SE. 2005. Comparative efficacy and immunogenicity of replication- defective, recombinant glycoprotein and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J. Virol. 79:410-418.
11. McLean CS, Ertuck M, Jennings R, Challanain DN, Minson AC, Duncan I, Boursnell ME, Inglis SC. 1994. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1. J. Infect. Dis. 170:1100-1109.
12. Manservigi R, Boero A, Argnani R, Caselli E, Zucchini S, Miriagou V, Mavromara P, Cilli M, Grossi MP, Balboni PG, Cassai E. 2005. Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model. Vaccine 23:865-872.
13. Simms JR, Heath AW, Jennings R. 2000. Use of herpes simplex virus (HSV) type 1 ISCOMS 703 vaccine for prophylactic and therapeutic treatment of primary and recurrent HSV-2 infection in guinea pigs. J. Infect. Dis. 181:1240-1248.
14. de Bruyn G, Vargas-Cortez M, Warren T, Tyring SK, Fife KH, Lalezari J, Brady RC, Shahmanesh M, Kinghorn G, Beutnen KR, Patel R, Drehobl MA, Horner P, Kurtz TO, McDermott S, Wald A, Corey L. 2006. A randomized controlled trial of a replication-defective (gH deletion) herpes simplex virus vaccine for the treatment of recurrent herpes among immunocompetent subjects. Vaccine 24:914-920.
15. Straus SE, Wald A, Kost RG, McKenzie R, Langenberg AGM, Hohman P, Lekstrom J, Cox E, Nakamura M, Sekulovich R, Izu A, Dekker C, Corey L. 1997. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoprotein D and B: results of a placebo controlled vaccine trial. J. Infect. Dis. 176:1129-1134.
16. Khanna KM, Lepisto AJ, Decman V, Hendricks RL. 2004. Immune control of herpes simplex virus during latency. Curr. Opin. Immunol. 16:463-469.
17. Liu T, Khanna KM, Carriere BN, Hendricks RL. 2001. Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons. J. Virol. 75:11178-11184.
18. Mikloska Z, Ruckholdt M, Ghadiminejad I, Dunckley H, Denis M, Cunningham AL. 2000. Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-γ and IL-12 production. J. Immunol. 164:5167-5176.
19. + CTL responses. Vaccine 23:236-246.
20. + T cells in innate and adaptive immune control of genital herpes simplex virus type 2 infection in mice. J. Gen. Virol. 82:845-853.
21. Verjans GM, Hintzen RQ, van Dun JM, Poot A, Millikan JC, Laman JD, Langerak AW, Kinchington PR, Osterhaus AD. 2007. Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc. Natl. Acad. Sci. U. S. A. 104:3496-3501.
22. Schacker T, Zeh J, Hu HL, Hill E, Corey L. 1998. Frequency of symptomatic and asymptomatic herpes simplex virus type 2 reactivations among human immunodeficiency virus-infected men. J. Infect. Dis. 178: 1616-1622.
23. + T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions. J. Virol. 68:2803-2810.
24. Koelle DM, Frank JM, Johnson ML, Kwok WW. 1998. Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions. J. Virol. 72:7476-7483.
25. Skoberne M, Larson S, Price J, Zielinski V, Lundberg A, Gierahn T, Cohane K, Warren T, Leone P, Scott EP, Grossman H, Davis A, Long D, Flechtner JB. 2012. Abstr. 37th Int. Herpesvirus Workshop, Calgary, Canada, abstr 6.05.
26. Pedersen G, Major D, Roseby S, Wood J, Madhun AS, Cox RJ. 2011. MatrixMadjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model. Influenza Other Respi. Viruses 5:426-437
27. Taylor JM, Lin E, Susmarski N, Yoon M, Zago A, Ware CF, Pfeffer K, Miyoshi J, Takai Y, Spear PG. 2007. Alternative entry receptors for herpes simplex virus and their roles in disease. Cell Host Microbe 2:19-28.
28. Tessier DC, Thomas DY, Khouri HE, Laliberie F, Vernet T. 1991. Enhanced secretion from insect cells of a foreign protein fused to the honeybee melittin signal peptide. Gene 98:177-183.
29. Kowalski J, Adkins K, Gangolli S, Ren J, Arendt H, DeStefano J, Obregon J, Tummolo D, Natuk RJ, Brown TP, Parks CL, Udem SA, Long D. 2007. Evaluation of neurovirulence and biodistribution of Venezuelan equine encephalitis replicon particles expressing herpes simplex virus type 2 glycoprotein D. Vaccine 25:2296-2305.
30. Picard MD, Cohane KP, Gierahn TM, Higgins DE, Flechtner JB. 2012. High-throughput proteomic screening identifies Chlamydia trachomatis antigens that are capable of eliciting T cell and antibody responses that provide protection against vaginal challenge. Vaccine 30:4387-4393.
31. Yewdall AW, Drutman SB, Jinwala F, Bahjat KS, Bhardwaj N. 2010. CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. PLoS One 5:e11144. doi:10.1371 /journal.pone.0011144.
32. Bernstein DI, Farlay N, Bravo FJ, Earwood J, McNeal M, Fairman J, Cardin R. 2010. The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine 28:3748-3753.
33. Stanberry LR, Bernstein DI, Burke RL, Pachl C, Myers MG. 1987. Vaccination with recombinant herpes simplex virus glycoproteins: protection against initial and recurrent genital herpes. J. Infect. Dis. 155:914-920.
34. Bright H, Perez DL, Christy C, Cockle P, Eyles JE, Hammond D, Khodai T, Lang S, West K, Loudon RT. 2012. The efficacy of HSV-2 vaccines based on gD and gB is enhanced by the addition of ICP27. Vaccine 30:7529-7535.
35. Hoshino Y, Pesnicak L, Dowdell KC, Burbelo PD, Knipe DM, Straus SE, Cohen JI. 2009. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. J. Infect. Dis. 200:1088-1095.
36. Posavad CM, Koelle DM, Corey L. 1996. High frequency of CD8+ cytotoxic T-lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes. J. Virol. 70:8165-8168.
37. Stanberry LR, Kern ER, Richards JT, Abbott TM, Overall JC, Jr. 1982. Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. J. Infect. Dis. 146:397-404.
38. Skoberne M, Cardin R, Kazimirova A, Larson S, Zielinski V, Garvie D, Lundberg A, Bernstein DI, Flechtner JB, Long D. 2012. Abstr. 37th Int. Herpesvirus Workshop, Calgary, Canada, abstr 6.09.
39. ++ T cells requires gamma interferon and either perforin-or fas-mediated cytolytic mechanisms. J. Virol. 79: 14546-14554
40. Koelle DM, Corey L 2003. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev. 16:96-113.
41. Cunningham AL, Diefenbach RJ, Miranda-Saksena M, Bosnjak L, Kim M, Jones C, Douglas MW. 2006. The cycle of human herpes simplex virus infection: virus transport and immune control. J. Infect. Dis. 194:S11-S18.
42. Laing KJ, Dong L, Sidney J, Sette A, Koelle DM. 2012. Immunology in the Clinic Review Series; focus on host responses: T cell responses to herpes simplex viruses. Clin. Exp. Immunol. 167:47-58.
43. Liu T, Khanna KM, Chen X, Fink DJ, Hendricks RL. 2000. CD8(+) T cells can block herpes virus type 1 (HSV-1) reactivation from latency in sensory neurons. J. Exp. Med. 191:1459-1466.
44. Franchini M, Abril C, Schwerdel C, Ruedel C, Ackerman M, Suter M. 2001. Protective T-cell-based immunity induced in neonatal mice by a single replicative cycle of herpes simplex virus. J. Virol. 75:83-89.
45. Posavad CM, Huang ML, Barcy S, Koelle DM, Corey L. 2000. Long term persistence of herpes simplex virus-specific CD8+CTL in persons with frequently recurring genital herpes. J. Immunol. 165:1146.
46. Mertz GJ. 2008. Asymptomatic shedding of herpes simplex virus 1 and 2: implications for prevention of transmission. J. Infect. Dis. 198:1098-1100.
47. Sacks SL, Griffiths PD. 2004. HSV shedding. Antiviral Res. 63(Suppl 1):S19-S26.
48. Straus SE, Corey L, Burke RL, Savarese B, Barnum G, Krause PR, Kost RG, Meier JL, Sekulovich R, Adair SF, Dekker CL. 1994. Placebocontrolled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 343: 1460-1463.
49. Stanberry LR. 2004. Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11:161A-169A.
50. Posavad CM, Remington M, Mueller DE, Zhao L, Margaret AS, Wald A, Corey L. 2010. Detailed characterization of T cell responses to herpes simplex virus-2 in immune seronegative persons. J. Immunol. 184:3250-3259.
51. Kohl S, Charlebois ED, Sigouroudinla M, Goldbeck C, Hartog K, Sekulovich RE, Langenberg AGM, Burke RL. 2000. Limited antibodydependent cellular cytotoxicity antibody response induced by a herpes simplex virus type 2 subunit vaccine. J. Infect. Dis. 181:335-339.
52. Mikloska Z, Kesson AM, Penfold ME, Cunningham AL. 1996. Herpes simplex virus protein targets CD4 and CD8 lymphocyte cytotoxicity in cultured epidermal karinocytes treated with interferon-gamma. J. Infect. Dis. 173:7.
53. Mikloska Z, Sanna P, Cunningham AL. 1999. Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro. J. Virol. 73:5934-5944.
54. Torseth JW, Cohen GH, Eisenberg RJ, Berman PW, Laskey LA, Cerini CP, Heilman CJ, Kewar S, Merigan TC. 1987. Native and recombinant herpes simplex virus type 1 envelope proteins induce human immune T-lymphocyte response. J. Virol. 61:1532-1539.
55. Madhun AS, Haaheim LR, Nilsen MV, Cox RJ. 2009. Intramuscular Matrix M-adjuvanted virosomal H5H1 vaccine induced high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine 27:7367-7376.
56. Lövgren Bengtsson K, Morein M, Osterhaus A. 2011. ISCOM technology- based Matrix M adjuvant; success in future vaccine relies on formulation. Expert Rev. Vaccines 10:401-403.
57. Meseda CA, Elkins KL, Merchlinsky MJ, Weir JP. 2002. Prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA alone. J. Infect. Dis. 186:1065-1073.
58. Braun RP, Dong L, Jerome S, Herber R, Roberts LK, Payne LG. 2008. Multi-antigenic DNA immunization using herpes simplex virus type 2 genomic fragments. Hum. Vaccin. 4:36-43.
59. Martin S, Zhu X, Silverstein SJ, Courtney RJ, Yao F, Jenkins FJ, Rouse BT. 1990. Murine cytotoxic T lymphocytes specific for herpes simplex virus type 1 recognize the immediate early protein ICP4 but not ICP0. J. Gen. Virol. 71:2391-2399.
60. Martin RM, Brady JL, Lew AM. 1998. The need for IgG2c specific antiserum when isotyping antibodies from C57BL/6 and NOD mice. J. Immunol. Methods 212:187-192.
61. Mosmann TR. 1992. T lymphocyte subsets, cytokines and effector functions. Ann. N. Y. Acad. Sci. 664:89-92.
62. Ishizaka ST, Piacente P, Silva J, Mishkin EM. 1995. IgG subtype is correlated with efficiency of passive protection and effector function of anti-herpes simplex virus glycoproteinDmonoclonal antibodies. J. Infect. Dis. 172:1108-1111.
63. Simms JR, Jennings R, Richardson VJ, Heath AW. 2002. Large-scale comparison of experimental adjuvants with herpes simplex virus vaccine reveals a correlation of protection with IgG2a and IgG2b responses. J. Med. Virol. 68:82-91.
64. McKendall RR, Woo W. 1988. Murine IgG subclass responses to herpes simplex virus type 1 and polypeptides. J. Gen. Virol. 69:847-857.
65. Coleman RM, Nahmias AJ, Williams SC, Phillips DJ, Black CM, Reimer CB. 1985. IgG subclass antibodies to herpes simplex virus. J. Infect. Dis. 151:929-936.
66. Thomsen AR, Volkert M, Marker O. 1985. Different isotype profiles of virus-specific antibodies in acute and persistent lymphocyte choriomeningitis virus infection in mice. Immunology 55:213-223.
67. Bourne N, Milligan GN, Stanberry LR, Stegall R, Pyles RB. 2005. Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J. Infect. Dis. 192:2117-2123.
68. Stanberry LR, Burke RL, Myers MG. 1988. Herpes simplex virus glycoprotein treatment of recurrent genital herpes. J. Infect. Dis. 157:156-163.
69. Awasthi S, Zumbrun EE, Si H, Wang F, Shaw CE, Cai M, Lubinski JM, Barret SM, Balliet JW, Flynn JA, Casimiro DR, Bryan JT, Friedman HM. 2012. Live attenuated herpes simplex virus 2 glycoprotein E deletion mutant as a vaccine candidate defective in neuronal spread. J. Virol. 86: 4586-4598.